18 February, 2022
The CAR-T ARI-0001 developed by the Hospital Clínic obtains the PRIME designation from the European Medicines Agency
ARI-0001 is a CAR-T therapy that has been developed at Hospital Clínic for the treatment of acute lymphoblastic leukaemia. In February 2021, the Spanish Agency for Medicines and Health Products (AEMPS) approved its use and it became the first treatment with genetically modified cells and fully developed in Europe that was approved by a regulatory agency. The path of ARI-0001 has not stopped here, and now the European Medicines Agency (EMA) has granted it the PRIME designation, which means that it has become a priority for the agency thus offering its support for an evaluation acceleration of this therapy.
23 December, 2021
The Hospital Clínic Group develops a second CAR-T, suitable for multiple myeloma resistant to treatment
The Hospital Clínic Group of Barcelona along with the August Pi and Sunyer Biomedical Research Institute (IDIBAPS) have developed a new CAR-T, the ARI-0002h, for patients with multiple myeloma resistant to habitual treatments. The results of a clinical trial, recently presented in the American Society of Hematology (ASH), which was held in Atlanta, have demonstrated that this new CAR-T for multiple myeloma is capable of getting a response rate of up to 75% after a year of treatment and that in 60% of patients that have complete remission and without residual disease, results that are, without doubt, very hopeful.